RxDoctor Payments Data

Alexander Gilbert, MD

Nephrology · Washington, DCNPI 1457346454

Payments from drug & device makers

What this record shows

3 manufacturers reported payments, led by GSK at 54.0% of the total. Reporting peaked in 2023 at $318 and has fallen 63.5% since, to $116 in 2025. That places this record below the midpoint for nephrology clinicians in DC, where the typical reported total is $513.

$500in general payments, 2019–2025

Across 5 payments — averaging $99.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$270
  • Sanofi-aventis U.S. LLC$182
  • Mallinckrodt Hospital Products Inc.$48
$40,205in research payments, 2019–2025

Across 12 payments — averaging $3350.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$24K
  • Shire North American Group Inc$15K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K

What the payments were for

  • Consulting fees$27054%
  • Food & beverage$23046%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$500 in reported general payments places this provider in the 45th percentile of 62 nephrology providers in District of Columbia.

See all nephrology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$135,362
Medicare patients
280
Services billed
857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tacrolimus44$3,869
Mycophenolate Mofetil21$2,594
Valganciclovir Hcl20$2,104
Cinacalcet Hcl13$1,541
Nifedipine ErNifedipine37$1,120
Pantoprazole Sodium67$679
Carvedilol55$552
Famotidine49$489
Tamsulosin Hcl32$393
Prednisone63$279
Amlodipine Besylate30$232
Clonidine Hcl17$168
Metoprolol Tartrate25$135
Atorvastatin Calcium17$93
Losartan Potassium17$82

Paid to pharmacies, not to this prescriber.

Other nephrology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →